Beijing Strong Biotechnologies (SZSE:300406) Debt-to-Equity : 0.30 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Beijing Strong Biotechnologies Debt-to-Equity?

Beijing Strong Biotechnologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥5 Mil. Beijing Strong Biotechnologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,164 Mil. Beijing Strong Biotechnologies's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥3,848 Mil. Beijing Strong Biotechnologies's debt to equity for the quarter that ended in Mar. 2024 was 0.30.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Beijing Strong Biotechnologies's Debt-to-Equity or its related term are showing as below:

SZSE:300406' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.1 Max: 0.39
Current: 0.3

During the past 13 years, the highest Debt-to-Equity Ratio of Beijing Strong Biotechnologies was 0.39. The lowest was 0.00. And the median was 0.10.

SZSE:300406's Debt-to-Equity is ranked worse than
55.1% of 196 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs SZSE:300406: 0.30

Beijing Strong Biotechnologies Debt-to-Equity Historical Data

The historical data trend for Beijing Strong Biotechnologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Strong Biotechnologies Debt-to-Equity Chart

Beijing Strong Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.10

0.39

0.34

0.31

Beijing Strong Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.33	0.33	0.31	0.31	0.30

Competitive Comparison of Beijing Strong Biotechnologies's Debt-to-Equity

For the Diagnostics & Research subindustry, Beijing Strong Biotechnologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Strong Biotechnologies's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Beijing Strong Biotechnologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Beijing Strong Biotechnologies's Debt-to-Equity falls into.

Beijing Strong Biotechnologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Beijing Strong Biotechnologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.968	+	1131.66)	/	3724.592
	=	0.30

Beijing Strong Biotechnologies's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.228	+	1163.505)	/	3847.753
	=	0.30

Beijing Strong Biotechnologies (SZSE:300406) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Beijing Strong Biotechnologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Beijing Strong Biotechnologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Strong Biotechnologies (SZSE:300406) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Beijing Strong Biotechnologies Inc (SZSE:300406) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 15 Hua Yuan Dong Lu, 5th Floor, Kuang Yi Building, Haidian District, Beijing, CHN, 100191

Website

http://www.bsbe.com.cn

Beijing Strong Biotechnologies Inc is a China-based provider of in-vitro (IVD) diagnostics products and service. The company is engaged in the research, development, production, and sale of IVD products. It also provides diversified clinical diagnosis solutions to customers. Its products include clinical biochemistry testing, coagulation testing, blood typing, serology and automated blood grouping analyzer. The firm has established a clinical biochemistry platform of the enzymatic method (including enzymatic cycling method), immunoturbidimetric method, and latex immunoturbidimetric method.

Beijing Strong Biotechnologies (SZSE:300406) Headlines

No Headlines